Coupons & Offers
Highlights
composition with strength
Repaglinide (0.5mg)
description
Manages type 2 diabetes effectively, increases insulin release quickly, adjunct to diet and exercise, not for type 1 diabetes
key benefits
Treatment of Type 2 diabetes mellitus
side effects
Headache and Hypoglycemia (low blood glucose level)
how to use
Take this medicine in the exact dose and duration as prescribed by your doctor
alcohol interaction
Unsafe
pregnancy interaction
Consult Your Doctor
lactation interaction
Consult Your Doctor
driving interaction
Caution
kidney interaction
Caution
liver interaction
Caution
Information
disclaimer
The contents and images displayed on this Platform are for informational purposes only and are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of a registered medical practitioner with any questions you may have regarding a medical condition or the use of any product. Do not disregard professional medical advice or delay seeking it because of something you have read on this Platform.We intend to support, not replace, the doctor-patient relationship.
While we make every effort to ensure the information provided is accurate and up-to-date, we strongly recommend reviewing product labels, batch numbers, manufacturing and packaging details, as well as any warnings and usage instructions before using or consuming any product.
customer care details
In case of any issue, contact us
E-mail address: support@zeptonow.com
Seller Name
Drogheria Sellers Private Limited
Seller Address
Brigade IRV, 9th & 10th Floors, Nallurhalli, White Field, Bangalore, Banglore, Karnataka, India, 560066 For Support ReachOut : support+drogheria@zeptonow.com
Pharmacy License No.
MH-MZ4-581161, MH-MZ4-581162
Manufacturer or Marketer Name
Torrent Pharmaceuticals Limited
Manufacturer or Marketer Address
16Th Floor, Godrej Bkc, Plot C, G Block, Bandra-Kurla Complex, Bandra (East), Mumbai 400 051, India
Country of Origin
GERMANY (Deutschland)
Shelf Life
36 months
Expires on or after
October 2026
